Details for New Drug Application (NDA): 217660
✉ Email this page to a colleague
NDA 217660 describes TRIKAFTA (COPACKAGED), which is a drug marketed by Vertex Pharms Inc and is included in two NDAs. It is available from one supplier. There are thirty-two patents protecting this drug. Additional details are available on the TRIKAFTA (COPACKAGED) profile page.
The generic ingredient in TRIKAFTA (COPACKAGED) is elexacaftor, ivacaftor, tezacaftor; ivacaftor. One supplier is listed for this compound. Additional details are available on the elexacaftor, ivacaftor, tezacaftor; ivacaftor profile page.
The generic ingredient in TRIKAFTA (COPACKAGED) is elexacaftor, ivacaftor, tezacaftor; ivacaftor. One supplier is listed for this compound. Additional details are available on the elexacaftor, ivacaftor, tezacaftor; ivacaftor profile page.
Summary for 217660
| Tradename: | TRIKAFTA (COPACKAGED) |
| Applicant: | Vertex Pharms Inc |
| Ingredient: | elexacaftor, ivacaftor, tezacaftor; ivacaftor |
| Patents: | 31 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 217660
Generic Entry Date for 217660*:
Constraining patent/regulatory exclusivity:
Dosage:
GRANULES;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 217660
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | GRANULES;ORAL | 217660 | NDA | Vertex Pharmaceuticals Incorporated | 51167-445 | 51167-445-01 | 4 PACKAGE in 1 CARTON (51167-445-01) / 1 KIT in 1 PACKAGE * 1 GRANULE in 1 PACKET (51167-545-07) * 1 GRANULE in 1 PACKET (51167-645-07) |
| TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | GRANULES;ORAL | 217660 | NDA | Vertex Pharmaceuticals Incorporated | 51167-446 | 51167-446-01 | 4 PACKAGE in 1 CARTON (51167-446-01) / 1 KIT in 1 PACKAGE * 1 GRANULE in 1 PACKET (51167-846-07) * 1 GRANULE in 1 PACKET (51167-746-07) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | GRANULES;ORAL | Strength | 80MG, 60MG, 40MG;59.5MG | ||||
| Approval Date: | Apr 26, 2023 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Oct 21, 2024 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Regulatory Exclusivity Expiration: | Apr 26, 2026 | ||||||||
| Regulatory Exclusivity Use: | NEW PRODUCT | ||||||||
| Regulatory Exclusivity Expiration: | Apr 26, 2030 | ||||||||
| Regulatory Exclusivity Use: | TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 2 YEARS TO LESS THAN 6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA | ||||||||
Complete Access Available with Subscription
